The Effects of Supratherapeutic Doses of Duloxetine on Blood Pressure and Pulse Rate
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The effects of supratherapeutic dosages of duloxetine, a serotonin and norepinephrine reuptake inhibitor, on blood pressure and pulse rate were assessed in a multicenter, double-blind, randomized, placebo-controlled, crossover study in 117 healthy women aged 19 to 74 years. Dosages were escalated from 60 mg twice daily (BID) to 200 mg BID over 16 days. Vital signs were monitored at baseline, before morning dosing, and sequentially at steady state. Duloxetine produced increases in supine systolic and diastolic blood pressures, which reached maximums of approximately 12 mm Hg and approximately 7 mm Hg above baseline, respectively, during dosing at 120 mg BID and then stabilized. Supine pulse rate increased gradually with dose, reaching 10 to 12 bpm above baseline after 4 days of dosing at 200 mg BID. Duloxetine caused changes in orthostatic blood pressures and pulse rate that reached plateau values after 3 to 4 days of dosing at 160 mg BID and were generally not associated with subjectively reported orthostatic-related adverse events. All vital signs normalized by 1 to 2 days after study drug discontinuation. Prehypertensive subjects may become hypertensive upon initial duloxetine dosing, but this can be predicted from predose blood pressure. Short-term supratherapeutic duloxetine dosages up to 200 mg BID are not well tolerated but are generally not associated with severe, clinically important adverse events. Overall, the types of adverse events reported in this study were similar to those in other studies of duloxetine in healthy subjects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Detke, M. J., Lu, Y., Goldstein, D. J., Hayes, J. R., & Demitrack, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0407 · Cited by 384
Duloxetine in the Treatment of Major Depressive Disorder: A Double-Blind Clinical Trial
Goldstein, D. J., Mallinckrodt, C., Lu, Y., & Demitrack, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0309 · Cited by 334
Goldstein, D. J., Lu, Y., Detke, M. J., Wiltse, C., Mallinckrodt, C., & Demitrack, M. A. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000132448.65972.d9 · Cited by 314
Kihara, T., & Ikeda, M. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24303-8 · Cited by 123
Cited by
Serotonin and Blood Pressure Regulation
Watts, S. W., Morrison, S. F., Davis, R. P., & Barman, S. M. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004697 · Cited by 396
Licht, C. M. M., de Geus, E. J. C., Seldenrijk, A., van Hout, H. P. J., Zitman, F. G., van Dyck, R., & Penninx, B. W. J. H. (2009) · Hypertension · doi:10.1161/hypertensionaha.108.126698 · Cited by 319
Cardiovascular adverse effects of newer antidepressants
Mago, R., Tripathi, N., & Andrade, C. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.908709 · Cited by 54
“The cardiovascular effects of supratherapeutic doses of duloxetine were assessed in a study of 117 women, aged 19–74 years, in whom the dose of duloxetine was increased over 16 days from 120 mg/d to 400 mg/d [74].”
BackgroundZhong, Z., Wang, L., Wen, X., Liu, Y., Fan, Y., & Liu, Z. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s141832 · Cited by 46
“A previous study reported that duloxetine at supratherapeutic doses increases supine SBP and DBP by maxima of ~12 mmHg and 7 mmHg above baseline, respectively.(15) Doses of venlafaxine and duloxetine in the included trials of our analysis varied between 75–375 mg/d and 40–120 mg/d, respectively.”
Metadata
- Authors
- Derby, M. A., Zhang, L., Chappell, J. C., Gonzales, C. R., Callaghan, J. T., Leibowitz, M., Ereshefsky, L., Hoelscher, D., Leese, P. T., & Mitchell, M. I.
- Venue
- Journal of Cardiovascular Pharmacology
- Published
- 2007-06
- Volume
- 49
- Issue
- 6
- Pages
- 384-393
- ISSN
- 0160-2446 (ISSN-L)
- OpenAlex
- W2023128716
- Cited by
- 36
- References
- 4
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.